China Medical System (HKG:0867) has obtained approval for clinical trials of its CMS-D005 injection from China's National Medical Products Administration, a Wednesday bourse filing said.
The pharmaceutical innovation and commercialization company can conduct a clinical trial to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of the drug in healthy and overweight/obese adult subjects in China.
CMS-D005 can be developed in the future to treat obesity/overweightedness, metabolic dysfunction-associated steatohepatitis, type 2 diabetes, and other metabolism-related diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments